Assess changes in ctDNA
to help clarify equivocal scans2,3
The tissue-free test that predicts treatment response
before standard imaging.1,2
>50% reduction in ctDNA is associated with
significantly longer progression-free survival (PFS).2,3
*Median turnaround time from sample receipt to results.
†Testing must occur 4-10 weeks after therapy initiation.1,2
Results
in 9 days4*
Important note: Guardant360 Response was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Covered by Medicare
for patients receiving immunotherapy†